Filing Flows › Aquestive Therapeutics (AQST) › Guidance & outlook
Aquestive Therapeutics (AQST) guidance and outlook
Aquestive Therapeutics (AQST) reaffirmed its guidance on Nov 3, 2026: Revenue $46.0M–$50.0M for . Aquestive Therapeutics' 10-Q filed Nov 3, 2026 makes 38 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | $46.0M–$50.0M | reaffirmed |
From the earnings release filed Nov 3, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 3, 2026
- We manufacture licensed products at our facilities and anticipate that our current manufacturing capacity is sufficient for commercial quantities of our licensed products and product candidates currently in development.
- On January 30, 2026, the Company received a CRL that focused on administration and labeling guidance.
- Based on feedback from regulatory agencies, the Company expects to submit regulatory applications by utilizing its existing clinical data.
- The Company expects to submit a New Drug Submission to Health Canada in the fourth quarter of 2026 and plans to file in the European Union in the first quarter of 2027.
- The data from these clinical studies formed the basis for the EOP2 meeting with the FDA in December of 2022, which provided clarity as to the FDA’s expectations regarding key clinical program areas for design of revised dosing instructions expected for use in our pivotal clinical trial.
- • AQST-108 (epinephrine) topical gel – Our product candidate, AQST‑108, is generated from our AdrenaVerse™ platform which contains a library of over twenty epinephrine prodrugs intended to control absorption and conversion rates across a variety of possible dosage forms and delivery sites.
- The Company expects to conduct additional clinical work beginning in the first quarter of 2027.
- Eton will be responsible for U.S. commercialization, while the Company received a $10,000 upfront license fee and is eligible to receive up to $47,500 in contingent regulatory and sales-based milestone payments and mid-teens royalties on net sales.
- The Company will remain the exclusive manufacturer and supplier of Libervant under a 20-year supply agreement, subject to specified exceptions.
- We expect future manufacture and supply revenue from licensed products to be based on volume demand for existing licensed products, and for manufacturing and supply rights under license and supply agreements for existing or new agreements for successful product development collaborations.
- Accordingly, the duration of our R&D projects may range from several months to approximately three years.
- We expect our R&D expenses to continue to be significant over the next several years as we continue to develop existing product candidates such as Anaphylm, AQST-108, and others, and as we identify and develop or acquire additional product candidates and technologies.
Aquestive Therapeutics' latest quarter
Aquestive Therapeutics, Q3 2026: revenue $7.6M (-41% year over year), operating margin -191.5%, net loss $16.5M, operating cash flow −$7.0M. The chart follows the revenue to costs, profit and cash.
Questions
Did Aquestive Therapeutics raise or lower its guidance?
Aquestive Therapeutics (AQST) reaffirmed its guidance on Nov 3, 2026: Revenue $46.0M–$50.0M for .
What does Aquestive Therapeutics expect?
We manufacture licensed products at our facilities and anticipate that our current manufacturing capacity is sufficient for commercial quantities of our licensed products and product candidates currently in development. On January 30, 2026, the Company received a CRL that focused on administration and labeling guidance. Based on feedback from regulatory agencies, the Company expects to submit regulatory applications by utilizing its existing clinical data.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.